Table of Content


Winter 2019, Vol. 27 No. 4

Hong Kong J. Dermatol. Venereol. (2019) 27, 181-184

Case Report

Vasculitic ulcer after programmed death-ligand 1 inhibitor therapy in a patient with metastatic ovarian cancer


E Choi, J Huang, C Tan


Programmed death-ligand 1 (PD-L1) inhibitors are monoclonal antibodies used in the treatment of certain cancers by enhancing a patient's immune system. They are therefore associated with immune-related side effects including cerebral vasculitis. We report a patient who developed a cutaneous vasculitic ulcer likely secondary to PD-L1 inhibitor therapy for metastatic ovarian cancer. She was treated and improved with prednisolone, colchicine and discontinuation of the drug. This case highlights a cutaneous manifesation of PD-L1 therapy, which although not life-threatening, may allow for early detection of PD-L1 treatment toxicity.


Keywords: Monoclonal antibody, ovarian cancer, programmed death-ligand 1, ulcer, vasculitis

關鍵詞: 單克隆抗體、卵巢癌、細胞程式死亡-配體1、潰瘍、血管炎